Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Advances in Gerontology
Published in: Advances in Gerontology 3/2020

01-07-2020 | Alzheimer's Disease

Plasmalogens in the Pathophysiology and Therapy of Age-Specific Diseases

Authors: O. Yu. Kytikova, T. P. Novgorodtseva, M. V. Antonyuk, T. A. Gvozdenko

Published in: Advances in Gerontology | Issue 3/2020

Login to get access

Abstract

The pathogenesis of age-related diseases such as metabolic syndrome, type-2 diabetes, Parkinson’s disease, and Alzheimer’s disease is associated with oxidative stress and chronic inflammation. Impairment of redox homeostasis is accompanied by the development of peroxisome dysfunction and impaired biosynthesis of plasmalogens, which may be associated with aging and the development of age-dependent pathology. Plasmalogens, which reflect the functional activity of peroxisomes, can serve not only as potential biomarkers of diseases associated with oxidative stress and aging but also as an important therapeutic target. The purpose of this review was to analyze the current knowledge of understudied biological and pathological aspects of plasmalogen participation in the pathophysiology of neurodegenerative and metabolic diseases of older persons. An understanding of the role of plasmalogens in the pathophysiology of these diseases can lead to the development of effective diagnostic and prognostic biomarkers, as well as treatment methods for neurodegenerative and metabolic diseases of older people.
Literature
1.
Danilova, A.L., Shul’gina, L.V., Rybchenko, A.A., and Shabanov, G.A., Influence of natural 1-O-alkyl-glycerols on the protective status of organism in elderly people, Mezhdunar. Zh. Prikl. Fundam. Issled., 2016, no. 12, pp. 1194–1198.
2.
Alzheimer’s Association, Alzheimer’s disease facts and figures, Alzheimer’s Dementia, 2017, vol. 13, pp. 325–373.
3.
André, A., Juanéda, P., Sébédio, J., and Chardigny, J., Plasmalogen metabolism-related enzymes in rat brain during aging: influence of n-3 fatty acid intake, Biochimie, 2006, vol. 88, pp. 103–111.
4.
Argyriou, C., D’Agostino, M.D., and Braverman, N., Peroxisome biogenesis disorders, Transl. Sci. Rare Dis., 2016, vol. 1, pp. 111–144.PubMedPubMedCentral
5.
Araujo, A.B. and Wittert, G.A., Endocrinology of the aging male, Best Pract. Res. Clin. Endocrinol. Metab., 2011, vol. 25, pp. 303–319.PubMedPubMedCentral
6.
Bannister, C.A., Holden, S.E., Jenkins-Jones, S., et al., Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls, Diabetes Obes. Metab., 2014, vol. 16, pp. 1165–1173.PubMed
7.
Barzilai, N. and Ferrucci, L., Insulin resistance and aging: a cause or a protective response?, J. Gerontol., A, 2012, vol. 67, pp. 1329–1331.
8.
Brodde, A., Teigler, A., Brugger, B., et al., Impaired neurotransmission in ether lipid-deficient nerve terminals, Hum. Mol. Genet., 2012, vol. 21, pp. 2713–2724.PubMedPubMedCentral
9.
Broniec, A., Żądło, A., and Pawlak, A., Interaction of plasmenylcholine with free radicals in selected model systems, Free Radical Biol. Med., 2017, vol. 106, pp. 368–378.
10.
Braverman, N.E. and Moser, A.B., Functions of plasmalogen lipids in health and disease, Biochim. Biophys. Acta,Mol. Basis Dis., 2012, vol. 1822, pp. 1442–1452.
11.
Burch, J.B., Augustine, A.D., Frieden, L.A., et al., Advances in geroscience: impact on healthspan and chronic disease, J. Gerontol., A, 2014, vol. 69, pp. S1–S3.
12.
Chrysohoou, C., Panagiotakos, D., Pitsavos, C., et al., Low total testosterone levels are associated with the metabolic syndrome in elderly men: the role of body weight, lipids, insulin resistance, and inflammation; the Ikaria study, Rev. Diabetic Stud., 2013, vol. 10, pp. 27–38.PubMed
13.
Colas, R., Sassolas, A., Guichardant, M., et al., LDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets, Diabetologia, 2011, vol. 54, pp. 2931–2940.PubMedPubMedCentral
14.
Cui, Y., Liu, X., Wang, M., et al., Lysophosphatidylcholine and amide as metabolites for detecting Alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics, J. Neuropathol. Exp. Neurol., 2014, vol. 73, pp. 954–963.PubMed
15.
De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., et al., Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study, Neurology, 2018, vol. 91, pp. 139–142.
16.
Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med., 2002, vol. 346, pp. 393–403.PubMedCentral
17.
Dorninger, F., Moser, A.B., Kou, J., et al., Alterations in the plasma levels of specific choline phospholipids in Alzheimer’s disease mimic accelerated aging, J. Alzheimer’s Dis., 2018, vol. 62, pp. 841–854.
18.
Ermolenko, E.V., Latyshev, N.A., Sultanov, R.M., and Kasyanov, S.P., Technological approach of 1-O-alkyl-sn-glycerols separation from Berryteuthis magister squid liver oil, J. Food Sci. Technol., 2016, vol. 53, pp. 1722–1726.PubMed
19.
Gonzalez-Covarrubias, V., Beekman, M., Uh, H.W., et al., Lipidomics of familial longevity, Aging Cell, 2013, vol. 12, pp. 426–434.PubMedPubMedCentral
20.
Gonzalez-Dominguez, R., Garcia-Barrera, T., and Gomez-Ariza, J.L., Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer’s disease, J. Proteomics, 2014, vol. 104, pp. 37–47.PubMed
21.
Gvozdenko, T.A., Kytikova, O.Yu., Vitkina, T.I., and Borshchyov, P.V., Description of the immune system of residents of the Russian Far East during physiological aging, Adv. Gerontol., 2012, vol. 2, no. 4, pp. 319–322.
22.
Halter, J.B., Musi, N., McFarland Horne, F., et al., Diabetes and cardiovascular disease in older adults: current status and future directions, Diabetes, 2014, vol. 63, pp. 2578–2589.PubMedPubMedCentral
23.
Heller, J., Mirzazade, S., Romanzetti, S., et al., Impact of gender and genetics on emotion processing in Parkinson’s disease—a multimodal study, Neuroimage: Clin., 2018, vol. 18, pp. 305–314.
24.
Honsho, M., Abe, Y., and Fujiki, Y., Plasmalogen biosynthesis is spatiotemporally regulated by sensing plasmalogens in the inner leaflet of plasma membranes, Sci. Rep., 2017, vol. 7, p. 43936.PubMedPubMedCentral
25.
Hossain, M.S., Mineno, K., and Katafuchi, T., Neuronal orphan G-protein coupled receptor proteins mediate plasmalogens-induced activation of ERK and Akt signaling, PLoS One, 2016, vol. 11, p. 0150846.
26.
Hui, S.P., Chiba, H., and Kurosawa, T., Liquid chromatographymass spectrometric determination of plasmalogens in human plasma, Anal. Bioanal. Chem., 2011, vol. 400, pp. 1923–1931.PubMed
27.
Hyotylainen, T. and Oresic, M., Systems biology strategies to study lipidomes in health and disease, Prog. Lipid Res., 2014, vol. 55, pp. 43–60.PubMed
28.
Katafuchi, T., Ifuku, M., Mawatari, S., and Fujino, T., Effects of plasmalogens on systemic lipopolysaccharide-induced glial activation and β-amyloid accumulation in adult mice, Ann. N.Y. Acad. Sci., 2012, vol. 1262, pp. 85–92.PubMed
29.
Kawanishi, N., Kato, Y., Yokozeki, K., et al., Effects of aging on serum levels of lipid molecular species as determined by lipidomics analysis in Japanese men and women, Lipids Health Dis., 2018, vol. 17, p. 135.PubMedPubMedCentral
30.
Kennedy, B.K., Berger, S.L., Brunet, A., et al., Aging: a common driver of chronic diseases and a target for novel interventions, Cell, 2014, vol. 159, pp. 709–713.PubMedPubMedCentral
31.
Khan, A.U., Akram, M., Daniyal, M., and Zainab, R., Awareness and current knowledge of Parkinson disease: a neurodegenerative disorder, Int. J. Neurosci., 2018, vol. 1, p. 64.
32.
Koehrer, P., Acar, N., Saab, S., et al., Polyunsaturated fatty acids and plasmalogens in diabetics, Invest. Ophthalmol. Visual Sci., 2013, vol. 54, p. 1158.
33.
Kou, J., Kovacs, G.G., Höftberger, R., et al., Peroxisomal alterations in Alzheimer’s disease, Acta Neuropathol., 2011, vol. 122, pp. 271–283.PubMedPubMedCentral
34.
Kullenberg, D., Taylor, L.A., Schneider, M., and Massing, U., Health effects of dietary phospholipids, Lipids Health Dis., 2012, vol. 11, p. 3.PubMedPubMedCentral
35.
Kytikova, O.Yu., Gvozdenko, T.A., and Vitkina, T.I., Oxidative DNA damage in the pathogenesis of chronic obstructive pulmonary disease in older patients, Adv. Gerontol., 2017, vol. 7, no. 2, pp. 163–165.
36.
LeWitt, P.A., Li, J., Lu, M., et al., Metabolomic biomarkers as strong correlates of Parkinson disease progression, Neurology, 2017, vol. 88, pp. 862–869.PubMedPubMedCentral
37.
Liu, F.T., Ge, J.J., Wu, J.J., et al., Clinical, dopaminergic, and metabolic correlations in Parkinson disease: a dual-tracer PET study, Clin. Nucl. Med., 2018, vol. 43, pp. 562–571.PubMed
38.
Maeba, R., Nishimukai, M., Sakasegawa, S., et al., Plasma/serum plasmalogens: methods of analysis and clinical significance, Adv. Clin. Chem., 2015, vol. 70, pp. 31–94.PubMed
39.
Macleod, A.D., Henery, R., Nwajiugo, P.C., et al., Age-related selection bias in Parkinson’s disease research: are we recruiting the right participants?, Parkinsonism Relat. Disord., 2018, vol. 55, pp. 128–133.PubMed
40.
Mankidy, R., Ahiahonu, P.W., Ma, H., et al., Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study, Lipids Health Dis., 2010, vol. 9, p. 62.PubMedPubMedCentral
41.
Marques, A., Figorilli, M., Pereira, B., Derost, P., et al., Impulse control disorders in Parkinson’s disease patients with RLS: a cross sectional-study, Sleep Med., 2018, vol. 48, pp. 148–154.PubMed
42.
Magnusson, C.D. and Haraldsson, G.G., Ether lipids, Chem. Phys. Lipids, 2011, vol. 164, pp. 315–340.PubMed
43.
Mawatari, S., Katafuchi, T., Miake, Y., and Fujino, T., Dietary plasmalogen increases erythrocyte membrane plasmalogen in rats, Lipids Health Dis., 2012, vol. 11, pp. 161–168.PubMedPubMedCentral
44.
Messias, M.S.F., Mecatti, G.C., Priolli, D.G., and Carvalho, P.O., Plasmalogen lipids: functional mechanism and their involvement in gastrointestinal cancer, Lipids Health Dis., 2018, vol. 17, p. 41.PubMedPubMedCentral
45.
Miville-Godbout, E., Bourque, M., Morissette, M., et al., Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice, Brain Res., 2017, vol. 1674, pp. 70–76.PubMed
46.
Nakamura, Y., Shimizu, Y., Horibata, Y., et al., Changes of plasmalogen phospholipid levels during differentiation of induced pluripotent stem cells 409B2 to endothelial phenotype cells, Sci. Rep., 2017, vol. 7, p. 9377.PubMedPubMedCentral
47.
Nishimukai, M., Maeba, R., Yamazaki, Y., et al., Serum choline plasmalogens, particularly those with oleic acid in sn-2, are associated with proatherogenic state, J. Lipid Res., 2014, vol. 55, pp. 956–965.PubMedPubMedCentral
48.
Onodera, T., Futai, E., Kan, E., et al., Phosphatidyl-ethanolamine plasmalogen enhances the inhibiting effect of phosphatidylethanolamine on γ-secretase activity, J. Biochem., 2015, vol. 157, pp. 301–309.PubMed
49.
Oresic, M., Simell, S., Sysi-Aho, M., et al., Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes, J. Exp. Med., 2008, vol. 205, pp. 2975–2984.PubMedPubMedCentral
50.
Otoki, Y., Kato, S., Kimura, F., et al., Accurate quantitation of choline and ethanolamine plasmalogen molecular species in human plasma by liquid chromatography-tandem mass spectrometry, J. Pharm. Biomed. Anal., 2017, vol. 134, pp. 77–85.PubMed
51.
Pedrono, F., Khan, N.A., and Legrand, A.B., Regulation of calcium signaling by 1-O-alkylglycerols in human Jurkat T lymphocytes, Life Sci., 2004, vol. 74, pp. 2793–2801.PubMed
52.
Peng, Z., Dong, S., Tao, Y., et al., Metabolic syndrome contributes to cognitive impairment in patients with Parkinson’s disease, Parkinsonism Relat. Disord., 2018, vol. 55, pp. 68–74.PubMed
53.
Phillips, M.A., Childs, C.E., Calder, P.C., and Rogers, P.J., No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer’s disease: a randomised controlled trial, Int. J. Mol. Sci., 2015, vol. 16, pp. 24 600–24 613.
54.
Ren, H., Luo, C., Feng, Y., et al., Omega-3 polyunsaturated fatty acids promote amyloid-β clearance from the brain through mediating the function of the glymphatic system, FASEB J., 2017, vol. 31, pp. 282–293.PubMed
55.
Rhee, E.P., Cheng, S., Larson, M.G., et al., Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans, J. Clin. Invest., 2011, vol. 121, pp. 1402–1411.PubMedPubMedCentral
56.
Samson, S.L. and Garber, A.J., Metabolic syndrome, Endocrinol. Metab. Clin. North Am., 2014, vol. 43, pp. 1–23.PubMed
57.
Santamaria, F., Montella, S., Greco, L., et al., Obesity duration is associated to pulmonary function impairment in obese subjects, Obesity, 2011, vol. 8, pp. 1623–1628.
58.
Su, X.Q., Wang, J., and Sinclair, A.J., Plasmalogens and Alzheimer’s disease: a review, Lipids Health Dis., 2019, vol. 18, p. 100.PubMedPubMedCentral
59.
Fabelo, N., Martin, V., Santpere, G., et al., Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson’s disease and incidental Parkinson’s disease, Mol. Med., 2011, vol. 17, pp. 1107–1118.PubMedPubMedCentral
60.
Fernández, R., Garate, J., Lage, S., et al., Identification of biomarkers of necrosis in xenografts using imaging mass spectrometry, J. Am. Soc. Mass. Spectrom., 2015, vol. 27, pp. 244–254.
61.
Fujino, T., Yamada, T., Asada, T., et al., Efficacy and blood plasmalogen changes by oral administration of plasmalogen in patients with mild Alzheimer’s disease and mild cognitive impairment: a multicenter, randomized, double-blind, placebo-controlled trial, EBioMedicine, 2017, vol. 17, pp. 199–205.PubMedPubMedCentral
62.
Yamashita, S., Kiko, T., Fujiwara, H., et al., Alterations in the levels of amyloid-β, phospholipid hydroperoxide, and plasmalogen in the blood of patients with Alzheimer’s disease: possible interactions between amyloid-β and these lipids, J. Alzheimer’s Dis., 2015, vol. 50, pp. 527–537.
63.
Yarandi, S.S., Peterson, D.A., Treisman, G.J., et al., Modulatory effects of gut microbiota on the central nervous system: how gut could play a role in neuropsychiatric health and diseases, J. Neurogastroenterol. Motil., 2016, vol. 22, pp. 201–212.PubMedPubMedCentral
64.
Valcarcel-Ares, M.N., Tucsek, Z., Kiss, T., et al., Obesity in aging exacerbates Neuroinflammation, dysregulating synaptic function-related genes and altering eicosanoid synthesis in the mouse hippocampus: potential role in impaired synaptic plasticity and cognitive decline, J. Gerontol., A, 2019, vol. 54, pp. 290–298.
65.
66.
Wallner, S. and Schmitz, G., Plasmalogens the neglected regulatory and scavenging lipid species, Chem. Phys. Lipids, 2011, vol. 164, pp. 573–589.PubMed
67.
Weijers, R.N., Lipid composition of cell membranes and its relevance in type 2 diabetes mellitus, Curr. Diabetes Rev., 2012, vol. 8, pp. 390–400.PubMedPubMedCentral
68.
Wiesner, P., Leidl, K., Boettcher, A., et al., Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry, J. Lipid. Res., 2009, vol. 50, pp. 574–585.PubMed
69.
Werner, E.R., Keller, M.A., Sailer, S., et al., A novel assay for the introduction of the vinyl ether double bond into plasmalogens using pyrene-labeled substrates, J. Lipid. Res., 2018, vol. 59, pp. 901–909.PubMedPubMedCentral
70.
Zhao, H., Wang, C., Zhao, N., et al., Potential biomarkers of Parkinson’s disease revealed by plasma metabolic profiling, J. Chromatogr. B, 2018, vols. 1081–1082, pp. 101–108.
Metadata
Title
Plasmalogens in the Pathophysiology and Therapy of Age-Specific Diseases
Authors
O. Yu. Kytikova
T. P. Novgorodtseva
M. V. Antonyuk
T. A. Gvozdenko
Publication date
01-07-2020
Publisher
Pleiades Publishing
Published in
Advances in Gerontology / Issue 3/2020
Print ISSN: 2079-0570
Electronic ISSN: 2079-0589
DOI
https://doi.org/10.1134/S207905702003011X

Other articles of this Issue 3/2020

Advances in Gerontology 3/2020 Go to the issue

OriginalPaper

Stimulating Effect of the Water-Soluble Fraction from Brown Algae Fucus vesiculosus Extract on Cell Proliferation in the Tissue Culture of Young and Old Rats

OriginalPaper

Characteristics of Fibrosis and Collagen Metabolism Disorders in the Myocardial Interstitial Matrix of Patients with Arterial Hypertension and the Potential Use of Sartan Drugs for Their Treatment

OriginalPaper

U-133, a Chaperone Inducer, Eliminates Sleep Disturbances in a Model of the Preclinical Stage of Parkinson’s Disease in Aged Rats

OriginalPaper

Age-Related Dynamics of the Indicators of Protein, Lipid, Carbohydrate, and Purin Metabolism and the Level of Pituitary Hormones in the Blood of Healthy, 22- to 55-Year-Old Men

OriginalPaper

Diagnostic Criteria and Prevalence of Sarcopenia in the Elderly

OriginalPaper

Immunohistochemistry Data on the Structural and Functional Changes in the Vascular Endothelium of the Heart of Old Rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits